A personalized medicine product to assess the status of the PTEN gene.

PREZEON assesses loss of PTEN function in cancer patients, which is associated with more aggressive disease progression and poorer survival. The PTEN gene plays a major role in cell signaling pathways that are the target of cancer drugs such as EGFR inhibitors and mTOR inhibitors.

Early studies have identified PTEN expression as associated with improved drug response, several cancers including breast, colon, prostate, and glioma.